The prevalence of frailty was 33% among a US-wide cohort of patients with RMDs, with the highest rates found among those with fibromyalgia or CTDs.

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...